Mike Westby, CEO
Mike has 15 years' experience in Pharma R&D, having worked for both Roche and Pfizer. Mike has worked across the Research and Development spectrum and whilst at Pfizer he helped successfully develop a novel therapy for treatment of HIV infection. Mike also headed up Pfizer's Opportunities for Partnership in Medicine (OPM) Research Unit and was a member of the Research Leadership Team at Pfizer's R&D UK Laboratories. Mike trained in Molecular Biology and Biochemistry at University of Durham, obtained his PhD at Warwick University and then completed a postdoctoral research fellow at St George's Hospital Medical School.
Clive Dix, Chairman
Clive has over 30 years' experience in the pharmaceutical and biotechnology industries. He was CEO and co-founder of PowderMed Limited, which was sold to Pfizer Inc. in 2006 and CEO and co-founder of Convergence Pharmaceuticals Limited, which was sold to Biogen Inc. in 2015.
Other previous roles include: Senior Vice President of research and development at PowderJect Pharmaceuticals plc sold to Chiron in 2003, Chairman of the UK BioIndustry Association, Chairman of Crescendo Biologicals Limited and Chairman of Auralis Limited (acquired by ViroPharma Inc). Following post-doctoral roles and a period at Ciba-Geigy AG (now Novartis AG), Clive joined GlaxoWellcome plc where he became UK Research Director. Clive is currently Executive Chairman of C4X Discovery plc, Chairman of Touchlight Genetics Limited and Calchan Ltd."
Stuart Lawson, Chief Financial Officer
Stuart is CEO of the private investment group Animatrix Founders LLP, which holds a broad range of investments with the core focus being early stage medical research and technology. Stuart currently serves as CFO of group members Origin Sciences Limited, Grakn Labs Limited, Finsen Technologies Limited and The Ideaswise Foundation. He qualified as a Chartered Accountant before working as a Manager at KPMG. He then worked as a Finance Director before moving to and becoming Group CFO and European MD with a LSE fully quoted manufacturing company; during his time he led them through 16 global acquisitions.
Jonathan Synett, Director
Jonathan is the Managing Director of NCL Ventures, a specialist investment management firm focussing on high growth technology companies, predominantly in the medical and energy sectors.
Jonathan has over 15 years experience working with and investing in early stage, high growth businesses. As well as being the founder of a high growth health and wellness business, he has managed investment portfolios for two Ultra High Net Worth's, investing across a variety of sectors, including technology, renewables and healthcare. He holds a degree in Economics and History from Manchester University and an INSEAD MBA. Jonathan now manages both of NCL's technology funds, including the Discovery Park Fund and sits on the Board of a number of development stage businesses.
Manjit Rahelu PhD, Chief Business Officer
Manjit is a senior executive, with a strong science background (B.Sc Biochemistry, Ph. D. Immunology) and broad based technical, commercial and financial experience gained over two decades in the industry. He was the VP Business Development of Convergence Pharmaceuticals Ltd, where he led the deal team which culminated in the sale of the business by Biogen.
His multifunctional, international expertise was gained in blue chip (Pfizer, Sanofi, Novartis), mid-sized (UCB., Allergy Therapeutics) and Biotech companies (Calchan, Convergence) with leadership and functional experience in HQ and country affiliate roles. He brings business development expertise in M&A and product focused licensing on both the buy and sell side.